Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection

Journal of Pharmacy Practice

Volumn 26, Issue 5, 2013, Pages 498-505

  Gens, Krista D ^a   Elshaboury, Ramy H ^b   Holt, Jessica S ^b  

^a NORTH MEMORIAL MEDICAL CENTER   (United States)

^b ABBOTT NORTHWESTERN HOSPITAL   (United States)

Author keywords

C difficile vaccines; fecal bacteriotherapy; fecal transplantation; monoclonal antibodies; recurrent CDI

Indexed keywords

BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXIN C; CLOSTRIDIUM DIFFICILE VACCINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; ERUCTATION; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; FLATULENCE; GINGIVA PAIN; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PERITONITIS; PNEUMONIA; RHEUMATOID ARTHRITIS; SINUSITIS; SJOEGREN SYNDROME; STOMACH HEMORRHAGE; THERAPY EFFECT; TRANSPLANTATION; VACCINATION;

C DIFFICILE VACCINES; FECAL BACTERIOTHERAPY; FECAL TRANSPLANTATION; MONOCLONAL ANTIBODIES; RECURRENT CDI;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; FECES; HUMANS; INCIDENCE; RECURRENCE;

EID: 84884681207     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013499527     Document Type: Article

References (59)

1. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005 ; 5 (9). 549-557
2. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010 ; 31 (5). 431-455
3. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012 ; 55 (suppl 2). S65 - S70
4. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012 ; 55 (suppl 2). S88 - S92
5. Huebner ES, Surawicz CM. Treatment of recurrent Clostridium difficile diarrhea. Gastroenterol Hepatol. 2006 ; 2 (3). 203-208
6. Jiang ZD, Hoang LN, Lasco TM, et al. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013 ; 56 (7). 1059-1060
7. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004 ; 38 (6). 475-483
8. Rager KD, George LW, House JK, et al. Evaluation of rumen transfaunation after surgical correction of left-sided displacement of the abomasum in cows. J Am Vet Med Assoc. 2004 ; 225 (6). 915-920
9. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958 ; 44 (5). 854-859
10. Adlerberth I, Wold AE. Establishment of the gut microbiota in western infants. Acta Paediatr. 2009 ; 98 (2). 229-238
11. De La Cochetiere MF, Durand T, Lepage P, et al. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol. 2005 ; 43 (11). 5588-5592
12. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother. 1994 ; 38 (3). 409-414
13. Borody TJ, Campbell J. Fecal microbiota transplantation: current status and future directions. Expert Rev Gastroenterol Hepatol. 2011 ; 5 (6). 653-655
14. Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16s rRNA sequencing. PLoS Biol. 2008 ; 6 (11). e280
15. Jernberg C, Sullivan A, Edlund C, et al. Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. Appl Environ Microbiol. 2005 ; 71 (1). 501-506
16. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis. 1993 ; 16 (suppl 4). S214 - S218
17. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008 ; 197 (3). 435-438
18. Fouhy F, Guinane CM, Hussey S, et al. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother. 2012 ; 56 (11). 5811-5820
19. Manges AR, Labbe A, Loo VG, et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis. 2010 ; 202 (12). 1877-1884
20. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989 ; 1 (8648). 1156-1160
21. Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010 ; 44 (5). 354-360
22. Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010 ; 44 (8). 551-561
23. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012 ; 46 (2). 145-149
24. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 ; 368 (5). 407-415
25. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 ; 353 (23). 2433-2441
26. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012 ; 142 (3). 490-496
27. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012 ; 107 (7). 1079-1087
28. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011 ; 53 (10). 994-1002
29. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003 ; 36 (5). 580-585
30. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection. 2012 ; 40 (6). 643-648
31. El-Matary W, Simpson R, Ricketts-Burns N. Fecal microbiota transplantation: are we opening a can of worms?. Gastroenterology. 2012 ; 143 (2). e19
32. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'repoopulating' the gut. Microbiome. 2013 ; 1 (3). 1-12
33. Kelly CP. Fecal microbiota transplantation - an old therapy comes of age. N Engl J Med. 2013 ; 368 (5). 474-475
34. Khanna S, Pardi DS.. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012 ; 87 (11). 1106-1117
35. Garborg K, Waagsbo B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis. 2010 ; 42 (11-12). 857-861
36. Mellow MH, Kanatzar A. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection - results and follow-up. J Okla State Med Assoc. 2011 ; 104 (3). 89-91
37. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010 ; 44 (8). 562-566
38. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010 ; 8 (5). 471-473
39. Jorup-Rönström C, Hakanson A, Sandell S, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol. 2012 ; 47 (5). 548-552
40. Kassam Z, Hundal R, Marshall JK, et al. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med. 2012 ; 172 (2). 191-193
41. MacConnachie AA, Fox R, Kennedy DR, et al. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM. 2009 ; 102 (11). 781-784
42. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004 ; 22 (7). 848-856
43. Marozsan AJ, Ma D, Nagashima KA, et al. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis. 2012 ; 206 (5). 706-713
44. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010 ; 362 (3). 197-205
45. Safdar A. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010 ; 362 (15). 1444-1446
46. Leav BA, Blair B, Leney M, et al. Serum anti-toxin b antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010 ; 28 (4). 965-969
47. Steele J, Mukherjee J, Parry N, et al. Antibody against tcdb, but not TCDA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis. 2013 ; 207 (2). 323-330
48. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins a and b prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006 ; 74 (11). 6339-6347
49. Kyne L. Clostridium difficile - beyond antibiotics. N Engl J Med. 2010 ; 362 (3). 264-265
50. Gerding DN. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov Med. 2012 ; 13 (68). 75-83
51. Foglia G, Shah S, Luxemburger C, et al. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012 ; 30 (29). 4307-4309
52. Greenberg RN, Marbury TC, Foglia G, et al. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine. 2012 ; 30 (13). 2245-2249
53. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998 ; 351 (9103). 633-636
54. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol. 1985 ; 19 (3). 339-350
55. Merrigan MM, Sambol SP, Johnson S, et al. New approach to the management of Clostridium difficile infection: Colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents. 2009 ; 33 (suppl 1). S46 - S50
56. Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis. 2002 ; 186 (12). 1781-1789
57. Wilson KH, Sheagren JN. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis. 1983 ; 147 (4). 733-736
58. Seal D, Borriello SP, Barclay F, et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol. 1987 ; 6 (1). 51-53
59. Villano SA, Seiberling M, Tatarowicz W, et al. Evaluation of an oral suspension of vp20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother. 2012 ; 56 (10). 5224-5229